FULL STACK DIGITAL CELL
Live / Applied — Fourth extension granted (statement of use) (as of 11 Sept 2025)
What this means for you
Not registered yet, but its 29 Apr 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97388377
- Mark type
- Stylized text
- Filed
- 29 Apr 2022
- Published for opposition
- 18 Jul 2023
- Attorney of record
- Christina M. Licursi
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical compositions in the nature of chemical small molecules for treatment of cancer, autoimmune disorders, transplant rejections, inflammatory disease, immunological disorders, metabolic disorders, neurological disorders, genetic disorders, psychiatric disorders, gastroenterological disorders, renal disorders, cardiovascular disorders, dermatological disorders, respiratory disorders
- Class 009 — Scientific and electric apparatus: Recorded and downloadable software featuring machine learning and artificial intelligence for drug analysis in drug discovery and development; recorded and downloadable software incorporating artificial intelligence and machine learning models for collecting, analyzing, assessing, interpreting and predicting medical, health, transcriptional, genetic, genomic, pharmacogenomic, nutrigenomic, microbiomic, metabolomic, proteomic, biochemistry, and biomarker information, associations, conditions, outcomes, effects and risks
- Class 042 — Scientific and technological services: Bioinformatic services for scientific research purposes, namely, collecting and analyzing complex biological data through the use of artificial intelligence; computer assisted molecule design involving the use of artificial intelligence technology; cellular computer modeling, for scientific research purposes, for analyzing complex biological data through the use of artificial intelligence; providing online non-downloadable software featuring machine learning and artificial intelligence for drug analysis in drug discovery and development; scientific research, namely, research and analysis services in the scientific fields of artificial intelligence and machine learning analytics, healthcare, biomedical and genomic research; providing online non-downloadable software incorporating artificial intelligence and machine learning models for collecting, analyzing, assessing, interpreting and predicting medical, health, transcriptional, genetic, genomic, pharmacogenomic, nutrigenomic, microbiomic, metabolomic, proteomic, biochemistry, and biomarker information, associations, conditions, outcomes, effects and risks
Owner
- Cellarity, Inc., Somerville, MA, US
- Cellarity, Inc., Somerville, MA, US
Prosecution history
- 11 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 12 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Sept 2025 — SOU EXTENSION 4 GRANTED
- 11 Sept 2025 — SOU EXTENSION 4 FILED
- 11 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 12 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Mar 2025 — SOU EXTENSION 3 GRANTED
- 11 Mar 2025 — SOU EXTENSION 3 FILED
- 11 Mar 2025 — SOU TEAS EXTENSION RECEIVED
- 12 Sept 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Sept 2024 — SOU EXTENSION 2 GRANTED
- 12 Sept 2024 — SOU EXTENSION 2 FILED
- 12 Sept 2024 — SOU TEAS EXTENSION RECEIVED
- 09 Mar 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 08 Mar 2024 — SOU EXTENSION 1 GRANTED